EAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study finds
HELSINKI, June 23, 2025 /CNW/ -- New research presented today at the European Academy of Neurology (EAN) Congress 2025 reveals that frequent nightmares are associated with significantly accelerated biological ageing and a more than threefold increase in the risk of premature death. This study is the first to show that nightmares independently predict faster biological ageing and earlier mortality – even after accounting for other health issues.
Led by Dr Abidemi Otaiku of the UK Dementia Research Institute and Imperial College London, the study analysed data from 2,429 children aged 8 to 10 and 183,012 adults aged 26 to 86 across six long-term population cohorts.
Nightmare frequency in adults was self-reported at the start of the study, with participants followed for up to 19 years. For children, nightmare frequency was reported by their parents at the beginning of the study.
Results showed that adults reporting weekly nightmares were more than three times as likely to die prematurely (before age 70) compared to those who rarely or never experienced nightmares. Children and adults with more frequent nightmares also exhibited faster biological ageing, which accounted for approximately 40% of the heightened mortality risk.
Notably, weekly nightmares were found to be a stronger predictor of premature death than other established risk factors such as smoking, obesity, poor diet, and low physical activity.
"Our sleeping brains cannot distinguish dreams from reality", Dr Otaiku explained. "That's why nightmares often wake us up sweating, gasping for breath, and with our hearts pounding – because our fight-or-flight response has been triggered. This stress reaction can be even more intense than anything we experience while awake."
He continued, "Nightmares lead to prolonged elevations of cortisol, a stress hormone closely linked to faster cellular ageing. For those who frequently experience nightmares, this cumulative stress may significantly impact the ageing process. Additionally, nightmares disrupt both sleep quality and duration, impairing the body's essential overnight cellular restoration and repair. The combined effects of chronic stress and disrupted sleep likely contribute to the accelerated ageing of our cells and bodies."
The association between frequent nightmares and accelerated ageing remained consistent across all ages, sexes, ethnicities, and mental health statuses, indicating a universal effect. Even monthly nightmares were linked to faster ageing and increased mortality compared to rare or no nightmares, emphasising the importance of reducing nightmare frequency across the population.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
Diamond and Diamond Lawyers Pursue Class Action Lawsuit Against L'Oréal Over Alleged Cancer Risks from "Dark and Lovely" Hair Relaxers
VANCOUVER, BC, June 24, 2025 /CNW/ - Diamond and Diamond Lawyers has filed a proposed class action against L'Oréal and its subsidiaries, alleging the company failed to warn consumers, primarily women of colour, about serious health risks linked to its "Dark and Lovely" hair relaxer products. Filed in the Supreme Court of British Columbia, the lawsuit claims these relaxers contain unsafe levels of Endocrine Disrupting Chemicals (EDCs) that are associated with respiratory and cardiovascular problems, diabetes, as well as reproductive cancers, including uterine, endometrial and ovarian cancer. These chemicals can also cause fibroids, damage the nervous and immune systems, as well as lead to neurological and learning disabilities. " These products were marketed as safe for decades. Our lawsuit alleges that L'Oréal ignored scientific evidence and failed to take appropriate action," said Darryl Singer, Head of Class Actions at Diamond and Diamond Lawyers. The Plaintiffs allege that L'Oreal: Has sold and marketed toxic relaxer products since approximately 1970 Failed to test for or detect the presence of EDCs prior to sale Ignored consumer complaints and failed to initiate recalls or safety warnings Mislead the public through deceptive marketing, in violation of the Business Practices and Consumer Protection Act, Competition Act and Sale of Goods Act Scientific studies published in 2012 and 2021 highlighted significant links between hair relaxer use and reproductive health issues. Despite these findings, L'Oréal has not acknowledged any potential danger associated with the products. The lawsuit names two representative plaintiffs and seeks to certify a broader class of affected consumers across Canada.
Cision Canada
2 hours ago
- Cision Canada
Galaxia Takes Another Leap Forward in Canadian Space Exploration with the Launch of MÖBIUS -1
HALIFAX, NS, /CNW/ - Galaxia is thrilled to announce the launch of MÖBIUS-1 on Monday June 23, 2025. This is a groundbreaking moment for satellite development and the Canadian space industry. MÖBIUS -1 was deployed into orbit by SpaceX Falcon-9 rocket as part of the Transporter 14 mission. MÖBIUS ™'s platform and unique status as a software-defined satellite (SDS) differentiates it from traditional hardware and is the first virtual satellite as a service platform that has ever launched. The platform allows clients to adapt their observation goals and provide real-time data. As part of the Launch and Early Orbit Phase (LEOP) Galaxia's Space Command and Control Team has begun tracking and communicating with the spacecraft to ensure the satellite is in a stable orbit and will be ready for operation soon. With previous heritage in spaceborne systems, this launch marks Galaxia's first dedicated deployment of its proprietary software-defined satellite architecture. MÖBIUS-1 is not only the first commercial satellite to be built and launched in Atlantic Canada, but also a foundational step toward the first fully virtualized satellite system, similar to cloud computers on Earth. Designed to support MissionOne, Galaxia's turnkey space service, MÖBIUS-1 enables clients to deploy, update, and operate custom applications from Earth, using cloud-like infrastructure. From AI model execution to edge-based data analysis, MÖBIUS-1 makes advanced space capabilities accessible without requiring clients to build, launch, or directly manage their own satellites, lowering barriers, reducing latency, and dramatically accelerating time to orbit. Arad Gharagozli, CEO of Galaxia emphasized that "Our MÖBIUS platform turns satellites into smart, cloud-like platforms - updatable, intelligent, and sovereign by design." Galaxia's innovation and independence in Canadian space construction has been a tireless journey, and MÖBIUS -1 represents the culmination of such efforts. Arad added, this is just the beginning- MÖBIUS and it's derivatives will soon fill mission-critical gaps across sovereign defense and commercial markets." Built with Canadian software and hardware and operated through domestic ground infrastructure, MÖBIUS-1 enhances national sovereignty by enabling real-time, proactive monitoring, detection, and response to emerging threats, both commercial and defense-related. Its Earth Observation capabilities support a diverse range of applications including maritime security, tracking dark vessels and combating illegal fishing operations. As Canada builds toward independent space infrastructure, Galaxia is leading the charge, delivering scalable, intelligent systems that strengthen national defense and technological self-reliance.
Cision Canada
2 hours ago
- Cision Canada
CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM Français
Data presented simultaneously at the American Diabetes Association's ® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing weight loss intervention. 1 When adhering to treatment, weight loss of ≥5%, ≥20%, ≥25%, and ≥30% was observed in 97.6%, 60.2%, 40.4% and 23.1% of patients respectively at 68 weeks. 1* The REDEFINE clinical program is ongoing to further investigate efficacy and safety of CagriSema, including recently initiated REDEFINE 11. 2 MISSISSAUGA, ON, June 24, 2025 /CNW/ - This week, The New England Journal of Medicine (NEJM) published results from Novo Nordisk's phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes. 1 REDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo. 1 These data, along with the related phase 3 REDEFINE 2 study conducted in adults with overweight or obesity and type 2 diabetes, were presented during a scientific symposium at the American Diabetes Association's (ADA) 85th Scientific Sessions and published in NEJM. Dr. Harpreet Bajaj, Medical Director of Endocrine and Metabolic Research at LMC Healthcare/Centricity Research in Canada and clinical investigator on REDEFINE 2, stated: "In the newly published primary results of REDEFINE 1 and 2 trials, CagriSema, a dual-agonist (incretin and amylin), led to incremental benefits on weight loss and glucose levels compared to semaglutide alone, representing a new era for the next generation of obesity medications. The average weight reduction of over 20% from baseline in REDEFINE 1 among participants with overweight or obesity is very promising. The weight loss in REDEFINE 2, along with over 80% * of the participants achieving HbA1C target of ≤6.5% among participants with type 2 diabetes, marks a significant scientific advancement for Canadians living with obesity who require support beyond currently available GLP-1 RAs. These results are especially relevant to real-world practices, considering the flexibility in both the study protocols." CagriSema is an investigational product that combines the GLP-1 RA, semaglutide, with an amylin analogue, cagrilintide. The REDEFINE 1 trial found that treatment with CagriSema resulted in greater weight loss of 22.7% at 68 weeks versus 2.3% in the placebo group if all patients adhered to treatment. 1* When evaluating the treatment effect regardless of adherence, those treated with CagriSema achieved statistically significant weight loss of 20.4% at 68 weeks versus 3.0% for the placebo group. 1** In addition, a supportive secondary analysis showed that half (50.7%) of trial participants with obesity treated with CagriSema reached the threshold for non-obesity (BMI < 30 kg/m 2) at the end of treatment, from a mean BMI of 38 kg/m 2 at the start of treatment. In the placebo group,10.2% reached that threshold at 68 weeks. 1 Select confirmatory secondary endpoints showed that if all participants adhered to treatment 40.4% of those receiving CagriSema achieved a body weight reduction of ≥25%. * Additionally, 23.1% lost ≥30% of their body weight. 1* When applying the treatment policy estimand, 34.7% of participants treated with CagriSema achieved ≥25% body-weight reduction and 19.3% achieved ≥30% body-weight reduction. 1 ** In a prespecified analysis of 252 participants, the relative reduction in fat and lean soft-tissue mass from baseline to week 68 was -35.7% (fat mass) and -14.4% (lean soft-tissue mass) for those treated with CagriSema versus –5.7% and –4.3% for the placebo group, respectively. 1 Safety data generated in the REDEFINE 1 and 2 trials was comparable with the GLP-1 RA class. Overall, discontinuation rates due to adverse events were low, with 5.9% for CagriSema versus 3.7% for placebo in REDEFINE 1 and 8.4% with CagriSema versus 3% with placebo in REDEFINE 2. 1,3 In REDEFINE 1, adverse events were mainly gastrointestinal (79.6% in the CagriSema group vs. 39.9% with placebo) including nausea (55% vs. 12.6 %), constipation (30.7% vs. 11.6%), vomiting (26.1% vs. 4.1%) and were mostly transient and mild-to-moderate in severity. 1 Results from REDEFINE 2, a phase 3 study that evaluated the efficacy and safety of CagriSema plus lifestyle interventions in adults with obesity and type 2 diabetes (T2D), were also simultaneously presented during a scientific symposium at the ADA's Scientific Sessions and published in NEJM. 3 In REDEFINE 2, if all participants adhered to treatment, the estimated mean change in body weight from baseline to week 68 was –15.7% with CagriSema versus –3.1% with placebo. 3* When applying the treatment policy estimand, the estimated mean change in body weight from baseline to week 68 was –13.7% with CagriSema versus –3.4% with placebo. 3** A greater proportion of participants receiving CagriSema, compared with placebo, reduced their body weight by > 5% (83.6% vs. 30.8% of participants), ≥10% (65.6% vs. 10.3%), ≥15% (43.8% vs. 2.4%), and ≥20% (22.9% vs. 0.5%). 3 The safety results from CagriSema in REDEFINE 2 were similar to those reported in REDEFINE 1. 3 The REDEFINE clinical program will continue to assess the efficacy and safety of CagriSema. Most recently, Novo Nordisk initiated the REDEFINE 11 trial with the first patient visit occurring in early June 2025. REDEFINE 11 will explore further weight loss potential and safety of CagriSema 2.4 mg / 2.4 mg through a longer trial duration and other protocol changes compared to REDEFINE 1 and 2. About CagriSema CagriSema is being investigated by Novo Nordisk as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE program) and as a treatment for adults with type 2 diabetes (REIMAGINE program). CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and semaglutide 2.4 mg. About the REDEFINE clinical trial program REDEFINE is a phase 3 clinical development program with once-weekly subcutaneous CagriSema in obesity. REDEFINE 1 and REDEFINE 2 have enrolled approximately 4,600 adults with overweight or obesity. REDEFINE 1 was a double-blind, placebo-and active-controlled 68-week efficacy and safety phase 3 trial of once-weekly CagriSema, cagrilintide 2.4 mg and semaglutide 2.4 mg versus placebo in 3,417 adults with obesity or overweight with one or more comorbidities and without type 2 diabetes. 1 REDEFINE 2 was a double-blind, randomized, placebo- and controlled 68-week efficacy and safety phase 3 trial of once-weekly CagriSema versus placebo in 1,206 adults with type 2 diabetes and either obesity or overweight. 3 Multiple REDEFINE clinical trials are currently underway including: REDEFINE 3, an event-driven cardiovascular outcomes phase 3 trial; REDEFINE 4 an 84-week head-to-head efficacy and safety phase 3 trial of once-weekly CagriSema versus once-weekly tirzepatide; and REDEFINE 11, a phase 3 trial with longer duration and other protocol changes compared to REDEFINE 1 and 2. About Obesity in Canada Over 8 million Canadian adults are living with obesity, and many require support to effectively manage their condition. 4 The prevalence of obesity, which increases the risk of serious chronic illness, has grown over the last two decades. 4,5 Obesity is not a personal failure or a lack of willpower—obesity is a chronic disease. 6 Despite its widespread impact, obesity often goes untreated, leading to significant personal, societal, and economic consequences. 7 Just like other chronic diseases, obesity requires long-term management. 8 About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. SOURCE Novo Nordisk Canada Inc.
